Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
Sign Up to like & getrecommendations! Published in 2019 at "Cancer"
DOI: 10.1002/cncr.32206
Abstract: Nivolumab demonstrated durable responses and safety in patients with hepatocellular carcinoma (HCC) with Child‐Pugh class A cirrhosis in the CheckMate 040 trial, with rates of hepatotoxicity that were similar to those of non‐HCC populations. To… read more here.
Keywords: hepatocellular carcinoma; cirrhosis; safety; child pugh ... See more keywords
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32468
Abstract: BACKGROUND & AIMS Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable hepatocellular carcinoma (HCC). No evidence exists as to its use in routine clinical practice in patients with impaired… read more here.
Keywords: atezolizumab plus; hepatocellular carcinoma; child pugh; treatment ... See more keywords
Shear wave elastography prior to transjugular intrahepatic portosystemic shunt may predict the decrease in hepatic vein pressure gradient
Sign Up to like & getrecommendations! Published in 2018 at "Abdominal Radiology"
DOI: 10.1007/s00261-018-1795-6
Abstract: BackgroundTransjugular intrahepatic portosystemic shunt (TIPS) is a procedure used to treat portal hypertension complications. Our aim was to evaluate liver and spleen stiffness measurement (LSM and SSM, respectively) changes using acoustic radiation force impulse imaging… read more here.
Keywords: intrahepatic portosystemic; hvpg; lsm ssm; decrease ... See more keywords
Decreased Plasma Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Levels are Linked with Disease Severity in Patients with Liver Cirrhosis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Peptide Research and Therapeutics"
DOI: 10.1007/s10989-021-10163-6
Abstract: Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide that has been found to reduce liver inflammation and protect liver from steatosis. We aimed to measure the level of plasma PACAP in patients with liver… read more here.
Keywords: liver cirrhosis; child pugh; pacap; pacap levels ... See more keywords
Evaluating the Short-Term Clinical Efficacy of Magnetic Resonance Elastography in Patients with Budd-Chiari Syndrome.
Sign Up to like & getrecommendations! Published in 2021 at "Academic radiology"
DOI: 10.1016/j.acra.2021.02.016
Abstract: RATIONALE AND OBJECTIVES To investigate the clinical relevance of liver stiffness (LS) in evaluating liver function properties in patients with Budd-Chiari syndrome (BCS) with different severities and LS variation before and after endovascular intervention. MATERIALS… read more here.
Keywords: liver function; treatment; child; patients budd ... See more keywords
Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites
Sign Up to like & getrecommendations! Published in 2020 at "Translational Oncology"
DOI: 10.1016/j.tranon.2020.100864
Abstract: Background Currently, hepatocellular carcinoma (HCC) patients with refractory ascites (RA) have a very poor prognosis, and there are no effective treatments recommended by the guidelines. A treatment strategy that utilizes a transjugular intrahepatic portosystemic shunt… read more here.
Keywords: tips combined; treatment; child; hcc patients ... See more keywords
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Sign Up to like & getrecommendations! Published in 2018 at "Gastroenterology"
DOI: 10.1053/j.gastro.2018.04.008
Abstract: BACKGROUND & AIMS Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus-associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess… read more here.
Keywords: hcc; cirrhosis; associated cirrhosis; child pugh ... See more keywords
Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?
Sign Up to like & getrecommendations! Published in 2020 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2020.1788139
Abstract: Abstract Objective It remains controversial whether certain treatments should apply to HCC patients with ascites due to concerns about worsening liver function. The objective of the present study is to compare the prognostic performance of… read more here.
Keywords: liver function; function models; treatment; hcc patients ... See more keywords
Caspofungin dosage adjustments are not required for patients with Child–Pugh B or C cirrhosis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dky189
Abstract: Background Controversies remain over caspofungin dosage adjustments in cirrhosis, particularly Child-Pugh (CP) B or C. The product information for of caspofungin recommends a maintenance dose reduction from 50 to 35 mg for patients with CP-B cirrhosis.… read more here.
Keywords: caspofungin; cirrhosis; dosage adjustments; caspofungin dosage ... See more keywords
Child-Pugh Class B or C Liver Disease Increases the Risk of Early Mortality in Patients With Hepatitis C Undergoing Elective Total Joint Arthroplasty Regardless of Treatment Status.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical orthopaedics and related research"
DOI: 10.1097/corr.0000000000002631
Abstract: BACKGROUND Patients with hepatitis C virus (HCV) undergoing primary elective total joint arthroplasty (TJA) are at increased risk of postoperative complications. Patients with chronic liver disease and cirrhosis, specifically Child-Pugh Class B and C, who… read more here.
Keywords: disease; pugh class; mortality; early mortality ... See more keywords
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Hepatology"
DOI: 10.1097/hep.0000000000000030
Abstract: Background and Aims: Immunotherapy-based regimes have changed the management of HCC. However, evidence of efficacy in patients with impaired liver function is unknown. This systematic review and meta-analysis assesses survival of HCC patients and liver… read more here.
Keywords: review meta; liver dysfunction; meta analysis; immunotherapy ... See more keywords